Pharmacoeconomics of therapy for Guillain–Barré syndrome: plasma exchange and intravenous immunoglobulin

Tsai, Ching Piao; Wang, Kai Chen; Liu, Chih Yang; Sheng, Wen‐Yung; Lee, Tzu Chi

doi:10.1016/j.jocn.2006.03.020

Cited by 27 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 Rate calculated from number of cases and population data provided in the paper. 6 Date used in incidence calculations is date of first admission to hospital. …”

Section: Variation With Agementioning

confidence: 99%

“…Typical treatment regimens for GBS include plasma exchange and intravenous immunoglobulin. Both treatments are thought to be equally efficacious, but Tsai et al [6] showed that intravenous immunoglobulin may be cheaper due to patients having fewer complications and requiring a shorter stay in hospital; direct health care costs were estimated to be approximately USD 110,000 in the USA.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Epidemiology of Guillain-Barré Syndrome Worldwide

et al. 2008

View full text Add to dashboard Cite

Background: This systematic literature review of the epidemiology of Guillain-Barré syndrome (GBS) identifies trends in incidence rates by age, study method and cause of disease. It is important to have a reliable estimate of incidence to determine and investigate any changes: no previous systematic reviews of GBS have been found. Methods: After critical assessment of the reliability of the reported data, incidence rates were extracted from all relevant papers published between 1980 and 2008, identified through searches of Medline, Embase and Science Direct. Results: Sixty-three papers were included in this review; these studies were prospective, retrospective reviews of medical records or retrospective database studies. Ten studies reported on the incidence in children (0–15 years old), and found the annual incidence to be between 0.34 and 1.34/100,000. Most studies investigated populations in Europe and North America and reported similar annual incidence rates, i.e. between 0.84 and 1.91/100,000. A decrease in incidence over the time between the 1980s and 1990s was found. Up to 70% of cases of GBS were caused by antecedent infections. Conclusions: Our best estimate of the overall incidence of GBS was between 1.1/100,000/year and 1.8/100,000/year. The incidence of GBS increased with age after 50 years from 1.7/100,000/year to 3.3/100,000/year.

show abstract

“…5 Rate calculated from number of cases and population data provided in the paper. 6 Date used in incidence calculations is date of first admission to hospital. …”

Section: Variation With Agementioning

confidence: 99%

mentioning

confidence: 99%

The Epidemiology of Guillain-Barré Syndrome Worldwide

et al. 2008

View full text Add to dashboard Cite

show abstract

“…3 Third, the authors state that the incidence of complications in both groups is the same yet the cost of complications in the TPE-treated group is greater. 1 This observation is in contrast to randomized controlled clinical trial data that report additional complications with TPE in elderly patients. 5 Since pneumonia concomitant with IVIG therapy (1 patient out of 7) is likely treated in a similar fashion to pneumonia concomitant with TPE (2 patients out of 10), the sole difference in the cost of complications between the two therapies must be the septic patient who underwent TPE (1 patient out of 10).…”

Section: Dear Professor Kayementioning

confidence: 84%

“…1 Although there is little doubt that the efficacy of intravenous immunoglobulin (IVIG) and therapeutic plasma exchange (TPE) are similar in GBS, 2 the total cost of administration of these two therapies is still debated. This report highlights an important deficiency in the literature; however, I have reservations regarding the conclusions drawn in this report.…”

Section: Dear Professor Kayementioning

confidence: 99%

Comment on “Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin”

Buenz¹

2009

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…Several controlled studies have shown that the rate and severity of infections can be significantly reduced by ivIg therapy [123]. The survival rate in the patients concerned, however, was not improved [84,85,114].…”

Section: Hiv Infection In Infants and Small Childrenmentioning

confidence: 96%